Tau sits inside the neuron—it's where the actual death happens.
In a field long dominated by the pursuit of amyloid, Biogen has turned its attention to tau — the protein that accumulates inside neurons and has been theorized as a deeper driver of Alzheimer's cognitive decline. Phase 2 trial results for diranersen, presented this week at the Alzheimer's Association International Conference, showed meaningful slowing of cognitive decline alongside measurable reductions in brain tau levels, offering early evidence that a different biological pathway may hold therapeutic promise. The findings do not yet prove the drug will transform care, but they widen the horizon of possibility for millions of patients and families navigating a disease that has resisted treatment for generations.
- Decades of Alzheimer's research have centered on amyloid, and the modest results of that approach have left patients and researchers hungry for a genuinely different strategy.
- Diranersen's Phase 2 CELIA trial produced two signals that rarely arrive together: measurable tau reduction in the brain and meaningful slowing of cognitive decline compared to placebo.
- Because tau lives inside neurons while amyloid accumulates outside them, successfully targeting tau would represent not just a new drug but a new theory of intervention — one that may work earlier and more precisely.
- The field is holding its optimism carefully, knowing that Phase 2 success has preceded Phase 3 failure many times in Alzheimer's history, and that questions of safety, durability, and patient selection remain unanswered.
- Biogen's next move toward larger Phase 3 trials will determine whether tau-targeting becomes a genuine pillar of Alzheimer's treatment or another promising signal that fades under scrutiny.
Biogen this week unveiled Phase 2 data for diranersen, an experimental Alzheimer's drug designed to target tau — a protein that accumulates inside neurons and has long been suspected of driving the neurodegeneration that defines the disease. Presented at the Alzheimer's Association International Conference, the results from the CELIA trial showed that patients in the early stages of Alzheimer's who received the drug experienced meaningful slowing of cognitive decline and robust reductions in brain tau levels compared to those on placebo.
The significance of this extends beyond a single drug. For decades, Alzheimer's research has been dominated by the pursuit of amyloid, the protein that clusters outside neurons in the form of plaques. Approved therapies targeting amyloid have shown only modest clinical benefit, leaving the field searching for alternatives. Tau, which forms tangles inside neurons, has long been theorized as a more direct driver of cell death, and some researchers believe intervening on tau earlier in the disease — before widespread neuronal loss occurs — could prove more effective. Diranersen's early results lend preliminary weight to that hypothesis.
Still, the field is proceeding with measured optimism. Phase 2 trials establish whether a drug shows biological activity and at what dose — they are not designed to prove real-world benefit. Larger Phase 3 studies will be required to confirm that tau reduction translates into lasting cognitive protection, to identify which patients respond best, and to resolve open questions about safety and how tau-targeting drugs might work alongside or in sequence with existing amyloid therapies.
For the millions living with Alzheimer's and their families, the promise is real but the road remains long. If diranersen's early signals hold through larger trials, it could expand the treatment landscape and open the door to more personalized approaches to a disease that has, for too long, offered patients very little.
Biogen presented Phase 2 trial data this week for diranersen, an experimental Alzheimer's drug that takes aim at tau, a protein long suspected of driving cognitive decline in the disease. The results, unveiled at the Alzheimer's Association International Conference, showed that patients receiving the drug experienced meaningful clinical improvements alongside measurable reductions in tau accumulation in the brain. For a field that has spent decades chasing amyloid—the other major protein implicated in Alzheimer's pathology—this represents a significant pivot.
The trial, called CELIA, enrolled patients in the early stages of Alzheimer's disease and tracked their cognitive function and brain tau levels over the study period. Diranersen appeared to slow cognitive decline more effectively than placebo, and imaging data showed robust tau reduction in treated patients. The magnitude of these findings matters because tau tangles have long been theorized as a driver of neurodegeneration, yet few drugs have successfully targeted them in human trials. Most approved Alzheimer's treatments focus on clearing amyloid plaques, an approach that has shown modest clinical benefit at best.
What makes this development noteworthy is not just that the drug worked, but that it worked through a different mechanism. Tau exists inside neurons, while amyloid accumulates outside them. The two proteins may interact in ways that amplify damage, and some researchers have hypothesized that targeting tau earlier in the disease process—before widespread neuronal death occurs—could yield better outcomes than waiting to intervene on amyloid alone. Diranersen's performance in this early trial lends credence to that theory, at least preliminarily.
Still, the field is approaching these results with measured optimism. Phase 2 trials are designed to test whether a drug works and at what dose, not to prove it will help patients in the real world. Larger, longer Phase 3 studies will be needed to confirm that tau reduction translates into sustained cognitive benefit and to identify which patients are most likely to respond. There are also open questions about safety, tolerability, and how tau-targeting drugs might be combined with existing amyloid-focused therapies or used sequentially.
For the millions of people living with Alzheimer's disease and their families, the implications are significant if these early signals hold. A drug that can slow cognitive decline by targeting a different pathological pathway could expand the arsenal of treatments available and potentially allow for more personalized approaches to the disease. But the path from Phase 2 promise to Phase 3 confirmation to clinical practice is long and uncertain. Biogen's next step will be to move diranersen into larger trials, where the real test of whether tau-targeting drugs can reshape Alzheimer's treatment will begin.
Citas Notables
Tau-targeting represents a significant pivot from decades of amyloid-focused drug development in Alzheimer's research.— Biogen trial data and field consensus
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that this drug targets tau instead of amyloid? Aren't they both involved in Alzheimer's?
They are, but we've been betting almost everything on amyloid for twenty years. The drugs that clear amyloid work, but only a little. Tau sits inside the neuron itself—it's where the actual death happens. If you can stop tau early, before the cell dies, you might actually prevent the decline instead of just slowing it.
So this is a completely different approach?
Different enough. It's not that amyloid doesn't matter. It's that we may have been fighting the wrong battle, or fighting it too late. This trial suggests tau-first or tau-alongside might be the way forward.
What happens now? Does this drug go straight to patients?
No. Phase 2 just proves it works in a small group and is safe enough to test further. They need Phase 3—thousands of patients, years of follow-up—to show it actually slows real cognitive decline in the way people care about. That's where most drugs fail.
And if it does work in Phase 3?
Then Alzheimer's treatment changes. Instead of one pathway, you have two. Doctors could choose based on what's happening in each patient's brain. You might use both drugs together. The whole paradigm shifts.
How long until we know?
Years. Phase 3 trials in Alzheimer's typically run three to five years minimum. So we're looking at 2028, 2029 before we have real answers.